Pub Date : 2018-12-01DOI: 10.1007/s15015-018-4347-6
Judith Neumaier
{"title":"Checkpointinhibition plus Chemotherapie punktet beim SCLC","authors":"Judith Neumaier","doi":"10.1007/s15015-018-4347-6","DOIUrl":"https://doi.org/10.1007/s15015-018-4347-6","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72594345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-01DOI: 10.1007/s15015-018-4356-5
F. Trillsch, N. Ditsch, S. Mahner
{"title":"PARP-Inhibitoren halten Einzug in die Primärtherapie des fortgeschrittenen Ovarialkarzinoms","authors":"F. Trillsch, N. Ditsch, S. Mahner","doi":"10.1007/s15015-018-4356-5","DOIUrl":"https://doi.org/10.1007/s15015-018-4356-5","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77873194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}